ProfoundBio Revenue and Competitors
Estimated Revenue & Valuation
- ProfoundBio's estimated annual revenue is currently $5.4M per year.
- ProfoundBio's estimated revenue per employee is $542,500
Employee Data
- ProfoundBio has 10 Employees.
- ProfoundBio grew their employee count by -72% last year.
ProfoundBio's People
| Name | Title | Email/Phone |
|---|
ProfoundBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 41 | 5% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is ProfoundBio?
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages. The Company’s clinical stage programs are rinatabart sesutecan (Rina-S; PRO1184), an ADC targeting folate receptor alpha, PRO1160, an ADC targeting CD70, and PRO1107, an ADC targeting PTK7. ProfoundBio is headquartered in Seattle, WA, USA.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$5.4M
Revenue (est)
-72%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Woodinville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 10 | 0% | N/A |
#2 | $2.4M | 12 | 20% | N/A |
#3 | $1.2M | 14 | -7% | N/A |
#4 | $1.4M | 16 | -20% | N/A |
#5 | $1.6M | 18 | 13% | N/A |